110 related articles for article (PubMed ID: 34510754)
21. CRISPR/dCas9-mediated epigenetic modification reveals differential regulation of histone acetylation on Aspergillus niger secondary metabolite.
Li X; Huang L; Pan L; Wang B; Pan L
Microbiol Res; 2021 Apr; 245():126694. PubMed ID: 33482403
[TBL] [Abstract][Full Text] [Related]
22. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
[TBL] [Abstract][Full Text] [Related]
23. Incorporation of a Synthetic Amino Acid into dCas9 Improves Control of Gene Silencing.
Koopal B; Kruis AJ; Claassens NJ; Nobrega FL; van der Oost J
ACS Synth Biol; 2019 Feb; 8(2):216-222. PubMed ID: 30668910
[TBL] [Abstract][Full Text] [Related]
24. A CRISPRi-dCas9 System for Archaea and Its Use To Examine Gene Function during Nitrogen Fixation by Methanosarcina acetivorans.
Dhamad AE; Lessner DJ
Appl Environ Microbiol; 2020 Oct; 86(21):. PubMed ID: 32826220
[TBL] [Abstract][Full Text] [Related]
25. enChIP systems using different CRISPR orthologues and epitope tags.
Fujita T; Yuno M; Fujii H
BMC Res Notes; 2018 Feb; 11(1):154. PubMed ID: 29482606
[TBL] [Abstract][Full Text] [Related]
26. Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.
Garcia-Bloj B; Moses C; Sgro A; Plani-Lam J; Arooj M; Duffy C; Thiruvengadam S; Sorolla A; Rashwan R; Mancera RL; Leisewitz A; Swift-Scanlan T; Corvalan AH; Blancafort P
Oncotarget; 2016 Sep; 7(37):60535-60554. PubMed ID: 27528034
[TBL] [Abstract][Full Text] [Related]
27. Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers.
Gao X; Tsang JC; Gaba F; Wu D; Lu L; Liu P
Nucleic Acids Res; 2014 Nov; 42(20):e155. PubMed ID: 25223790
[TBL] [Abstract][Full Text] [Related]
28. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.
Zhao Q; Qian Q; Cao D; Yang J; Gui T; Shen K
J Ovarian Res; 2018 Apr; 11(1):31. PubMed ID: 29685168
[TBL] [Abstract][Full Text] [Related]
29. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer.
Chen YT; Hsu M; Lee P; Shin SJ; Mhawech-Fauceglia P; Odunsi K; Altorki NK; Song CJ; Jin BQ; Simpson AJ; Old LJ
Int J Cancer; 2009 Jun; 124(12):2893-8. PubMed ID: 19296537
[TBL] [Abstract][Full Text] [Related]
30. Localized delivery of CRISPR/dCas9 via layer-by-layer self-assembling peptide coating on nanofibers for neural tissue engineering.
Zhang K; Chooi WH; Liu S; Chin JS; Murray A; Nizetic D; Cheng D; Chew SY
Biomaterials; 2020 Oct; 256():120225. PubMed ID: 32738650
[TBL] [Abstract][Full Text] [Related]
31. Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy.
Liu Q; Wang C; Zheng Y; Zhao Y; Wang Y; Hao J; Zhao X; Yi K; Shi L; Kang C; Liu Y
Biomaterials; 2020 Nov; 258():120275. PubMed ID: 32798741
[TBL] [Abstract][Full Text] [Related]
32. CKM and TERT dual promoters drive CRISPR-dCas9 to specifically inhibit the malignant behavior of osteosarcoma cells.
Hu Y; Zhang H; Guo Z; Zhou J; Zhang W; Gong M; Wu J
Cell Mol Biol Lett; 2023 Jul; 28(1):52. PubMed ID: 37415116
[TBL] [Abstract][Full Text] [Related]
33. Enhancing stem cell survival in an ischemic heart by CRISPR-dCas9-based gene regulation.
Pan A; Weintraub NL; Tang Y
Med Hypotheses; 2014 Dec; 83(6):702-5. PubMed ID: 25459138
[TBL] [Abstract][Full Text] [Related]
34. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
35. RNA-guided transcriptional activation via CRISPR/dCas9 mimics overexpression phenotypes in Arabidopsis.
Park JJ; Dempewolf E; Zhang W; Wang ZY
PLoS One; 2017; 12(6):e0179410. PubMed ID: 28622347
[TBL] [Abstract][Full Text] [Related]
36. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
38. Rational gRNA design based on transcription factor binding data.
Bergenholm D; Dabirian Y; Ferreira R; Siewers V; David F; Nielsen J
Synth Biol (Oxf); 2021; 6(1):ysab014. PubMed ID: 34712839
[TBL] [Abstract][Full Text] [Related]
39. Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells.
Tummala R; Diegelman P; Fiuza SM; Batista de Carvalho LA; Marques MP; Kramer DL; Clark K; Vujcic S; Porter CW; Pendyala L
Oncol Rep; 2010 Jul; 24(1):15-24. PubMed ID: 20514439
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-dCas9-Guided and Telomerase-Responsive Nanosystem for Precise Anti-Cancer Drug Delivery.
Ma Y; Mao G; Wu G; Cui Z; Zhang XE; Huang W
ACS Appl Mater Interfaces; 2021 Feb; 13(7):7890-7896. PubMed ID: 33513005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
